-
-
Call more information
660-596-2224 -
Author: Michael Walter Cardiovascular Business Neuroscientists have developed a new protein, TAT-DP-2, that could limit stroke-related brain damage, sharing their findings in Science Advances. The protein was designed to prevent cell death through the disruption of two specific Kv2.1 channels. This keeps potassium from leaving the cells in question, which completely changes how they react during […]
Read MoreAUTHORS: Sylvie D. Aucoin, M.D., M.Sc., F.R.C.P.C. et al Anesthesiology 7 2020, Vol.133, 78-95. Background: A barrier to routine preoperative frailty assessment is the large number of frailty instruments described. Previous systematic reviews estimate the association of frailty with outcomes, but none have evaluated outcomes at the individual instrument level or specific to clinical assessment of frailty, […]
Read MoreBy Pat Anson Pain News Network Editor An experimental non-opioid pain reliever gives long-term relief for chronic low back pain, but questions remain about joint damage and other side effects from the drug, according to a large new study. Tanezumab is a humanized monoclonal antibody that targets nerve growth factor (NGF), a protein in the […]
Read MoreAUTHORS: Yeoh, Cindy B. MD et al Anesthesia & Analgesia: July 2020 – Volume 131 – Issue 1 – p 16-23 Abstract The novel coronavirus disease 2019 (COVID-19) was first reported in China in December 2019. Since then, it has spread across the world to become one of the most serious life-threatening pandemics since the […]
Read MoreAuthor: Michael Walter Cardiovascular Business News A single dose of selatogrel can safely provide heart attack patients with a “profound, rapid” antiplatelet response, according to a new study published in the Journal of the American College of Cardiology. There are multiple P2Y12 receptor antagonists currently available, the authors explained, but the antiplatelet effect often takes too long to […]
Read More